Global Nerve Stimulator Market Opportunities and Forecast 2020-2027

1 Report Prologue 11

2 Market Introduction 13

• 2.1 Research Objective 13
• 2.2 Assumptions & Limitations 13
  • 2.2.1 Assumptions 13
  • 2.2.2 Limitations 13

3 Research Methodology 15

• 3.1 Research Process 15
• 3.2 Primary Research 16
• 3.3 Secondary Research 16
• 3.4 Market Size Estimation 17

4 Market Dynamics 19

• 4.1 Introduction 19
• 4.2 Drivers 20
  • 4.2.1 Rising incidence of chronic health problems (Impact weightage: 35%) 20
  • 4.2.2 Technological improvements (Impact weightage: 35%) 21
  • 4.2.3 Increasing geriatric population (Impact weightage: 20%) 22
  • 4.2.4 Improved reimbursement policies in developed countries (Impact weightage: 10%) 23
• 4.3 Restrains 24
  • 4.3.1 Lack of skilled or trained physicians (Impact weightage: 60%) 24
  • 4.3.2 High cost of nerve stimulation therapy (Impact weightage: 40%) 25
• 4.4 Opportunity 26
  • 4.4.1 Increasing popularity of minimally invasive procedures across the globe 26
• 4.5 Macroeconomic Indicators 26

5 Market Factor Analysis 27

• 5.1 Porter’s Five Forces Model 27
  • 5.1.1 Bargaining Power of Suppliers 27
  • 5.1.2 Bargaining Power of Buyers 28
  • 5.1.3 Threat on New Entrants 28
  • 5.1.4 Threat of Substitutes 28
  • 5.1.5 Intensity of Rivalry 28
• 5.2 Value Chain Analysis 29
  • 5.2.1 R&D and Designing 29
  • 5.2.2 Manufacturing 29
  • 5.2.3 Distribution & Sales 30
  • 5.2.4 Post-sales Monitoring 30
• 5.3 Demand & Supply: Gap Analysis 31
• 5.4 Pricing Analysis 31

6 Global Nerve Stimulator Market by Type 32

• 6.1 Introduction 32
• 6.2 Deep Brain Stimulator (DBS) 33
• 6.3 Vagus Nerve Stimulator (VNS) 34
• 6.4 Spinal Cord Stimulator (SCS) 34

7 Global Nerve Stimulator Market by Applications 35

• 7.1 Introduction 35
• 7.2 Chronic Pain 36
• 7.3 Depression 37
• 7.4 Dystonia 37
• 7.5 Epilepsy 38
• 7.6 Parkinson’s Disease 38

8 Global Nerve Stimulator Market by End Users 39

• 8.1 Introduction 39
• 8.2 Ambulatory Surgical Centers 40
• 8.3 Hospital & Clinics 41
• 8.4 Trauma Centers 41

9 Global Nerve Stimulator Market by Regions 42

• 9.1 Introduction 42
• 9.2 Americas 43
  • 9.2.1 North America 46
    • 9.2.1.1 US 47
    • 9.2.1.2 Canada 49
  • 9.2.2 South America 50
• 9.3 Europe 52
  • 9.3.1 Western Germany 54
    • 9.3.1.1 Germany 56
    • 9.3.1.2 France 57
    • 9.3.1.3 Italy 59
    • 9.3.1.4 Spain 60
    • 9.3.1.5 UK 62
    • 9.3.1.6 Rest of Western Europe 63
  • 9.3.2 Eastern Europe 65
• 9.4 Asia Pacific 67
  • 9.4.1 China 69
  • 9.4.2 India 71
  • 9.4.3 Japan 72
  • 9.4.4 South Korea 74
  • 9.4.5 Australia 75
  • 9.4.6 Rest of Asia Pacific 77
• 9.5 Middle East & Africa 79
  • 9.5.1 UAE 81
  • 9.5.2 Saudi Arabia 83
  • 9.5.3 Oman 84
  • 9.5.4 Kuwait 86
  • 9.5.5 Qatar 87
  • 9.5.6 Rest of Middle East & Africa 89

10 Competitive Landscape 91

• 10.1 Introduction 91

11 Company Profile 92

• 11.1 Boston Scientific Corporation 92
  • 11.1.1 Company Overview 92
  • 11.1.2 Financials 92
  • 11.1.3 Products 92
  • 11.1.4 Strategy 92
  • 11.1.5 Key Developments 92
• 11.2 Cochlear ltd. 93
  • 11.2.1 Company Overview 93
  • 11.2.2 Financials 93
  • 11.2.3 Products 93
  • 11.2.4 Strategy 93
  • 11.2.5 Key Developments 93
• 11.3 Medtronic 94
  • 11.3.1 Company Overview 94
  • 11.3.2 Financials 94
  • 11.3.3 Products 94
  • 11.3.4 Strategy 94
  • 11.3.5 Key Developments 94
• 11.4 St Jude Medical, Inc. 95
  • 11.4.1 Company Overview 95
  • 11.4.2 Financials 95
  • 11.4.3 Products 95
  • 11.4.4 Strategy 95
  • 11.4.5 Key Developments 95
• 11.5 Cyberonics, Inc. 96
  • 11.5.1 Company Overview 96
  • 11.5.2 Financials 96
  • 11.5.3 Products 96
  • 11.5.4 Strategy 96
  • 11.5.5 Key Developments 96
• 11.6 Aleva Neurotherapeutics SA 97
  • 11.6.1 Company Overview 97
  • 11.6.2 Financials 97
  • 11.6.3 Products 97
  • 11.6.4 Strategy 97
  • 11.6.5 Key Developments 97
• 11.7 NeuroPace, Inc. 98
  • 11.7.1 Company Overview 98
  • 11.7.2 Financials 98
  • 11.7.3 Products 98
  • 11.7.4 Strategy 98
  • 11.7.5 Key Developments 98

12 Conclusion 99

• 12.1 Key Findings 99
  • 12.1.1 From CEO’s View Point 99
• 12.2 Key Companies to Watch 99

13 Appendix 100